Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4036 Target Snapshot

Cyclin-dependent kinase 5 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,500Compounds
348Assays
5Approved Drugs
2,013.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Cyclin-dependent kinase 5 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q00535. Start with chronic lymphocytic leukemia, then reuse UniProt Q00535 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with chronic lymphocytic leukemia, then reuse UniProt Q00535 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
chronic lymphocytic leukemia

Cyclin-dependent kinase 5 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with chronic lymphocytic leukemia because it currently carries late clinical support. Linked drugs include DINACICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 5 as ChEMBL target CHEMBL4036, mapped to UniProt Q00535. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 5
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4036
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q00535
Cyclin-dependent kinase 5
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cyclin-dependent kinase 5 is the right protein anchor across sources, using UniProt Q00535 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chronic lymphocytic leukemia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameCyclin-dependent kinase 5
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ00535
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCyclin-dependent kinase 5
UniProt AccessionQ00535
Component TypeProtein
Sequence Length292 aa

Cyclin-dependent kinase 5

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Cyclin-dependent kinase 5, mapped to UniProt Q00535. Sequence length is 292 aa.

Mapped IDQ00535
Review nameCyclin-dependent kinase 5
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Cyclin-dependent kinase 5 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
chronic lymphocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugDINACICLIB
Clinical signal Phase II
acute lymphoblastic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugDINACICLIB
Clinical signal Phase II
acute myeloid leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugDINACICLIB
Clinical signal Phase II
cystic fibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugSELICICLIB
Clinical signal Phase II
multiple myeloma
1 linked drug · 1 direct · 1 efficacy
Linked drugDINACICLIB
Clinical signal Phase II
non-small cell lung carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugSELICICLIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with chronic lymphocytic leukemia because it currently carries late clinical support. Linked drugs include DINACICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasechronic lymphocytic leukemia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
8
Phase III
23
Phase II
16
Phase I
Assay Mix

Activity Type Distribution

IC50573.0
KI1,048.0
KD392.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL384304 10.0 IC50 0.1 Clinical
CHEMBL2006674 9.5 Ki 0.3162 Preclinical
CHEMBL191003 9.3 Ki 0.5012 Preclinical
CHEMBL1980407 9.2 Ki 0.631 Preclinical
CHEMBL2103840 9.0 IC50 1.0 Clinical
CHEMBL3775792 9.0 IC50 1.0 Preclinical
CHEMBL4292930 9.0 IC50 1.0 Preclinical
CHEMBL5171657 9.0 IC50 1.0 Preclinical
CHEMBL5266005 9.0 IC50 1.0 Preclinical
CHEMBL1968930 8.9 Ki 1.259 Preclinical
Distribution

pChEMBL Value Distribution

118
5.0
161
5.5
139
6.0
136
6.5
95
7.0
78
7.5
42
8.0
6
8.5
23
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

ABEMACICLIB
CHEMBL3301610
Approved 2017
Properties Compare Identifier
PALBOCICLIB
CHEMBL189963
Approved 2015
Properties Compare Identifier
Assay Landscape

Assay Landscape

348
Total Assays
429
Tested Compounds
3
Assay Types
Binding — 346 assays, 311 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 243 282 6.6
cell-based format 55 4 9.0
subcellular format 29 22 6.2
assay format 19 3 5.6
Functional — 1 assays, 429 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 429 6.2
Toxicity — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine